# Allurion Technologies, Inc.: overview

ALUR · OTC · CIK 1964979 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alur.md) · [Financials](/companies/alur/financials.md) · [Filings](/companies/alur/filings.md) · [Insiders](/companies/alur/insiders.md)

Latest reported revenue: [$2.9m](/filings/0001193125-26-226960.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed May 15, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-226960).

## Last eight quarters

| Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.8](/filings/0000950170-25-112000.md) | [5.4](/filings/0001193125-25-284630.md) | [5.6 d](/filings/0001193125-26-130483.md) | [5.6](/filings/0001193125-26-226960.md) | [3.4](/filings/0000950170-25-110188.md) | [2.7](/filings/0001193125-25-284630.md) | [3.6 d](/filings/0001193125-26-130483.md) | [2.9](/filings/0001193125-26-226960.md) |
| Gross margin | % | [76.4%](/filings/0000950170-25-112000.md) | [58.0%](/filings/0001193125-25-284630.md) | [45.3% d](/filings/0001193125-26-130483.md) | [74.6%](/filings/0001193125-26-226960.md) | [73.9%](/filings/0000950170-25-110188.md) | [49.1%](/filings/0001193125-25-284630.md) | [44.5% d](/filings/0001193125-26-130483.md) | [41.7%](/filings/0001193125-26-226960.md) |
| Operating margin | % | [(79.4%)](/filings/0000950170-25-112000.md) | [(229.9%)](/filings/0001193125-25-284630.md) | [(306.1%) d](/filings/0001193125-26-130483.md) | [(130.5%)](/filings/0001193125-26-226960.md) | [(205.7%)](/filings/0000950170-25-110188.md) | [(362.3%)](/filings/0001193125-25-284630.md) | [(174.2%) d](/filings/0001193125-26-130483.md) | [(126.6%)](/filings/0001193125-26-226960.md) |
| Net margin | % | [(70.7%)](/filings/0001193125-25-284630.md) | [162.8%](/filings/0001193125-25-284630.md) | [(171.8%) d](/filings/0001193125-26-130483.md) | [(26.9%)](/filings/0001193125-26-226960.md) | [(276.3%)](/filings/0001193125-25-284630.md) | [(447.1%)](/filings/0001193125-25-284630.md) | [(167.0%) d](/filings/0001193125-26-130483.md) | [(206.8%)](/filings/0001193125-26-226960.md) |
| Diluted EPS | $ per share | [(4.34)](/filings/0000950170-25-112000.md) | [3.40](/filings/0001193125-25-284630.md) | not reported | [(0.31)](/filings/0001193125-26-226960.md) | [(1.28)](/filings/0000950170-25-110188.md) | [(1.53)](/filings/0001193125-25-284630.md) | not reported | [(0.46)](/filings/0001193125-26-226960.md) |
| Free cash flow | $m | [(9.4) d](/filings/0000950170-25-112000.md) | [(11.5) d](/filings/0001193125-25-284630.md) | [(13.3) d](/filings/0001193125-26-130483.md) | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [64.2](/filings/0000950170-25-111978.md) | [53.5](/filings/0000950170-25-111978.md) | [32.1](/filings/0001193125-26-130483.md) | [15.2](/filings/0001193125-26-130483.md) |
| Gross margin | % | [79.0%](/filings/0000950170-25-111978.md) | [77.6%](/filings/0000950170-25-111978.md) | [67.0%](/filings/0001193125-26-130483.md) | [62.8%](/filings/0001193125-26-130483.md) |
| Operating margin | % | [(49.9%)](/filings/0000950170-25-111978.md) | [(147.9%)](/filings/0000950170-25-111978.md) | [(156.3%)](/filings/0001193125-26-130483.md) | [(198.0%)](/filings/0001193125-26-130483.md) |
| Net margin | % | [(58.8%)](/filings/0000950170-25-111978.md) | [(154.9%)](/filings/0000950170-25-111978.md) | [(22.4%)](/filings/0001193125-26-130483.md) | [(188.8%)](/filings/0001193125-26-130483.md) |
| Diluted EPS | $ per share | [(37.75)](/filings/0000950170-25-111978.md) | [(59.38)](/filings/0000950170-25-111978.md) | [(3.20)](/filings/0001193125-26-130483.md) | [(3.81)](/filings/0001193125-26-130483.md) |
| Free cash flow | $m | [(48.5)](/filings/0000950170-25-111978.md) | [(65.6)](/filings/0000950170-25-111978.md) | [(42.9)](/filings/0001193125-26-130483.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alur/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

None of the funds in coverage reports a position in its latest 13F.

## Recent filings

[All 318 filings](/companies/alur/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-02 | 00:03 ET | [SCHEDULE 13D/A](/filings/0001493215-26-000166.md) | Ownership report, active investor, amended | 0001493215-26-000166 |
| 2026-08-24 | 21:30 ET | [8-K](/filings/0001193125-26-363811.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-363811 |
| 2026-07-24 | 20:50 ET | [8-K](/filings/0001193125-26-316202.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-316202 |
| 2026-07-23 | 21:19 ET | [SCHEDULE 13D/A](/filings/0001493215-26-000135.md) | Ownership report, active investor, amended | 0001493215-26-000135 |
| 2026-07-23 | 21:00 ET | [8-K](/filings/0001193125-26-314263.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-314263 |
| 2026-07-07 | 12:05 ET | [8-K](/filings/0001193125-26-296918.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-296918 |
| 2026-06-30 | 21:00 ET | [8-K](/filings/0001193125-26-290772.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-290772 |
| 2026-06-17 | 20:35 ET | [8-K](/filings/0001193125-26-274250.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-274250 |
| 2026-05-27 | 20:35 ET | [8-K](/filings/0001193125-26-242009.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001193125-26-242009 |
| 2026-05-15 | 20:30 ET | [10-Q](/filings/0001193125-26-226960.md) | Quarterly report, period 2026-03-31 | 0001193125-26-226960 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-130483.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1964979
- Tickers: ALUR, ALURW
- Exchange: OTC
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.